PD-1 inhibitor immunotherapy combined with targeted CSC therapy improved the effect of anti-tumor therapy [131, 132], which suggests that CSC is one of the potential factors for the failure of PD-1 inhibitor immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.